Detecting <i>Schisandrae Chinensis Fructus</i> and Its Chinese Patent Medicines with a Nucleotide Signature

• Main Authors: Wenjun Jiang, Li Ren, Mengyue Guo, Nitin Mantri, Sha Zhao, Xiaohui Pang
• Format: Article
• Language: English
• Published: MDPI AG 2019-05-01
• Series: Genes
• Subjects: Wuweizi; Chinese patent medicines; identification; nucleotide signature
• Online Access: https://www.mdpi.com/2073-4425/10/5/397

<i>Schisandrae Chinensis Fructus</i> (Wuweizi) is often adulterated with <i>Schisandrae Sphenantherae Fructus</i> (Nanwuweizi) in the herbal market. This adulteration is a threat to clinical treatment and safety. In this study, we aimed to develop a nucleotide signature for the identification of Wuweizi and its Chinese patent medicines based on the mini-DNA barcoding technique. We collected 49 samples to obtain internal transcribed spacer 2 (ITS2) sequences and developed a 26-bp nucleotide signature (5&#8242;-CGCTTTGCGACGCTCCCCTCCCTCCC-3&#8242;) on the basis of a single nucleotide polymorphism (SNP) site within the ITS2 region that is unique to Wuweizi. Then, using the nucleotide signature, we investigated 27 batches of commercial crude drug samples labeled as Wuweizi and eight batches of Chinese patent medicines containing Wuweizi. Results showed that eight commercial crude drug samples were adulterants and one of the Chinese patent medicines contained adulterants. The nucleotide signature can serve as an effective tool for identifying Wuweizi and its Chinese patent medicines and can thus be used to ensure clinical drug safety.